Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP1032122.RApUL5_rm7Oxc4aT2-vgXOMtOGbPVi8bh13Zq7TpAOXvQ130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP1032122.RApUL5_rm7Oxc4aT2-vgXOMtOGbPVi8bh13Zq7TpAOXvQ130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP1032122.RApUL5_rm7Oxc4aT2-vgXOMtOGbPVi8bh13Zq7TpAOXvQ130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP1032122.RApUL5_rm7Oxc4aT2-vgXOMtOGbPVi8bh13Zq7TpAOXvQ130_provenance.
- NP1032122.RApUL5_rm7Oxc4aT2-vgXOMtOGbPVi8bh13Zq7TpAOXvQ130_assertion description "[Taking advantage of our recently identified novel selective antagonist for the EP2 (PTGER2) subtype of PGE(2) receptor, we demonstrated that EP2 receptor activation could promote prostate cancer cell growth and invasion in vitro, accompanied by upregulation of the tumor-promoting inflammatory cytokines, such as IL-1? and IL-6.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1032122.RApUL5_rm7Oxc4aT2-vgXOMtOGbPVi8bh13Zq7TpAOXvQ130_provenance.
- NP1032122.RApUL5_rm7Oxc4aT2-vgXOMtOGbPVi8bh13Zq7TpAOXvQ130_assertion evidence source_evidence_literature NP1032122.RApUL5_rm7Oxc4aT2-vgXOMtOGbPVi8bh13Zq7TpAOXvQ130_provenance.
- NP1032122.RApUL5_rm7Oxc4aT2-vgXOMtOGbPVi8bh13Zq7TpAOXvQ130_assertion SIO_000772 23192657 NP1032122.RApUL5_rm7Oxc4aT2-vgXOMtOGbPVi8bh13Zq7TpAOXvQ130_provenance.
- NP1032122.RApUL5_rm7Oxc4aT2-vgXOMtOGbPVi8bh13Zq7TpAOXvQ130_assertion wasDerivedFrom befree-2016 NP1032122.RApUL5_rm7Oxc4aT2-vgXOMtOGbPVi8bh13Zq7TpAOXvQ130_provenance.
- NP1032122.RApUL5_rm7Oxc4aT2-vgXOMtOGbPVi8bh13Zq7TpAOXvQ130_assertion wasGeneratedBy ECO_0000203 NP1032122.RApUL5_rm7Oxc4aT2-vgXOMtOGbPVi8bh13Zq7TpAOXvQ130_provenance.
- befree-2016 importedOn "2016-02-19" NP1032122.RApUL5_rm7Oxc4aT2-vgXOMtOGbPVi8bh13Zq7TpAOXvQ130_provenance.